Suppr超能文献

微生物细胞制剂改善慢性便秘的疗效:一项随机、双盲、安慰剂对照试验。

Efficacy of microbial cell preparation in improving chronic constipation: a randomized, double-blind, placebo-controlled trial.

机构信息

Department of Surgery, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia.

出版信息

Clin Nutr. 2013 Dec;32(6):928-34. doi: 10.1016/j.clnu.2013.03.004. Epub 2013 Mar 13.

Abstract

BACKGROUND & AIMS: Probiotics is an emerging therapeutic agent which may alleviate the symptoms of constipation. We evaluated the effectiveness of microbial cell preparation (Hexbio(®)) containing fructooligosaccharide, Bifidobacterium and Lactobacillus in improving stool frequency and symptoms of chronic constipation.

METHODS

A total of 120 constipated adults diagnosed using Rome III criteria were randomized and given either microbial cell preparation or placebo to be consumed twice daily. Follow-up was done after a 7-day intervention based on a questionnaire which includes an assessment of symptom profile and a stool diary.

RESULTS

During the intervention period, the stool frequency was higher (p = 0.001) in the treatment group. Subjects experienced less straining (p = 0.001) and sensation of incomplete evacuation (p < 0.001), as well as improved stool consistency (p < 0.001) compared to the placebo group. While a higher proportion of subjects in the treatment group had a reduction in anorectal blockage sensation and having to defecate by manual maneuvers, the differences were not statistically significant.

CONCLUSION

The results suggest that microbial cell preparation is effective in improving stool frequency and stool consistency. Furthermore, it could reduce the symptoms of straining and sensation of incomplete evacuation in adults with chronic functional constipation.

MREC REG NO

866.59 (IRB, UMMC, Malaysia).

摘要

背景与目的

益生菌是一种新兴的治疗药物,可能缓解便秘症状。我们评估了含有低聚果糖、双歧杆菌和嗜酸乳杆菌的微生物细胞制剂(Hexbio(®))改善慢性便秘患者排便频率和症状的疗效。

方法

根据 Rome III 标准诊断的 120 例便秘成年人被随机分为微生物细胞制剂组或安慰剂组,每天口服 2 次。干预 7 天后通过问卷调查进行随访,评估症状谱和粪便日记。

结果

干预期间,治疗组的排便频率更高(p = 0.001)。与安慰剂组相比,治疗组患者排便费力(p = 0.001)和排便不尽感(p < 0.001)减轻,粪便稠度改善(p < 0.001)。治疗组中更多的患者感觉直肠阻塞感减轻,需要通过手法排便,但差异无统计学意义。

结论

结果表明,微生物细胞制剂可有效改善慢性功能性便秘患者的排便频率和粪便稠度。此外,它可以减轻排便费力和排便不尽感的症状。

MREC REG NO

866.59(马来西亚 UMMCIRB)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验